Table 5.

Considerations for future trials in survivors of AKI

Target the highest risk patients (i.e., severe AKI, preexisting CKD, nonrecovery at discharge)Flexible follow-up pathways that do not rely solely on in-person clinic visits with a level of intensity tailored to the patient’s needsLonger follow-up period for major adverse kidney events
Randomize patients as close to discharge as possible to ensure engagementEarly remote risk stratification by nurse/discharge planners to reach patients as soon as possible after dischargeFor rehospitalization/recurrent AKI, intervention must reach patients early (i.e., ≤7 days from discharge)
More prescriptive direction on when to use ACEi/ARBPatient-reported outcomes (e.g., symptom burden, frailty, anxiety)
  • ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.